Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389480 · ClinicalTrials.gov registry record · Phase 1
Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies
A Phase 1 study, sponsored by Arno Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00389480 is a Phase 1 study that has completed, run by Arno Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT00389480, a Phase 1 study, has completed, sponsored by Arno Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Hypothesis: AR-67 (formerly DB-67) represents a rationally engineered drug that possesses improved stability, toxicity, and efficacy compared to current Food and Drug Administration (FDA)-approved camptothecins, based on the extensive research of prior studies. Therefore, the investigators hypothesize that AR-67 (formerly DB-67) will be well-tolerated and efficacious in phase I clinical trials. This initial phase I trial will establish the maximum tolerated dose in humans, establish the toxicity profile, and define the appropriate dose of AR-67 (formerly DB-67) for future phase II and III clinical trials.
Interventions
- DRUG AR-67 (formerly DB-67)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389480
The ClinicalTrials.gov registry entry for NCT00389480 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arno Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AR-67 (formerly DB-67) is the first listed.
NCT00389480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389480 about?
NCT00389480 is a clinical study titled "Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies". Hypothesis: AR-67 (formerly DB-67) represents a rationally engineered drug that possesses improved stability, toxicity, and efficacy compared to current Food and Drug Administration (FDA)-approved camptothecins, based on the extensive research of prior studies. Therefore, the investigators hypothes...
What is the current status of trial NCT00389480?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2006-10. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00389480?
The interventions under investigation include: AR-67 (formerly DB-67) (DRUG).
Who is sponsoring clinical trial NCT00389480?
This trial is sponsored by Arno Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.